1dbk: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
[[Image:1dbk.jpg|left|200px]] | [[Image:1dbk.jpg|left|200px]] | ||
'''MOLECULAR BASIS OF CROSS-REACTIVITY AND THE LIMITS OF ANTIBODY-ANTIGEN COMPLEMENTARITY''' | {{Structure | ||
|PDB= 1dbk |SIZE=350|CAPTION= <scene name='initialview01'>1dbk</scene>, resolution 3.0Å | |||
|SITE= | |||
|LIGAND= <scene name='pdbligand=ANO:5-BETA-ANDROSTANE-3,17-DIONE'>ANO</scene> | |||
|ACTIVITY= | |||
|GENE= | |||
}} | |||
'''MOLECULAR BASIS OF CROSS-REACTIVITY AND THE LIMITS OF ANTIBODY-ANTIGEN COMPLEMENTARITY''' | |||
==Overview== | ==Overview== | ||
| Line 7: | Line 16: | ||
==About this Structure== | ==About this Structure== | ||
1DBK is a [ | 1DBK is a [[Protein complex]] structure of sequences from [http://en.wikipedia.org/wiki/ ]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1DBK OCA]. | ||
==Reference== | ==Reference== | ||
Molecular basis of crossreactivity and the limits of antibody-antigen complementarity., Arevalo JH, Taussig MJ, Wilson IA, Nature. 1993 Oct 28;365(6449):859-63. PMID:[http:// | Molecular basis of crossreactivity and the limits of antibody-antigen complementarity., Arevalo JH, Taussig MJ, Wilson IA, Nature. 1993 Oct 28;365(6449):859-63. PMID:[http://www.ncbi.nlm.nih.gov/pubmed/8413674 8413674] | ||
[[Category: Protein complex]] | [[Category: Protein complex]] | ||
[[Category: Arevalo, J H.]] | [[Category: Arevalo, J H.]] | ||
| Line 17: | Line 26: | ||
[[Category: immunoglobulin]] | [[Category: immunoglobulin]] | ||
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Mar 20 10:35:51 2008'' | ||
Revision as of 11:35, 20 March 2008
| |||||||
| , resolution 3.0Å | |||||||
|---|---|---|---|---|---|---|---|
| Ligands: | |||||||
| Coordinates: | save as pdb, mmCIF, xml | ||||||
MOLECULAR BASIS OF CROSS-REACTIVITY AND THE LIMITS OF ANTIBODY-ANTIGEN COMPLEMENTARITY
OverviewOverview
Two major unanswered questions concerning the specificity of antibodies are: how do structurally different antigens bind with high affinity to the same antibody, and what are the limits of the antibody combining site complementarity and flexibility that contribute to such crossreactivity? We report here a comparative analysis of the X-ray structures of five conformationally different steroids in complex with the Fab' fragment of an anti-progesterone antibody DB3 at 2.7 A. This antibody is unable to complement completely the shape of the hydrophobic antigen so that crossreactivity occurs with other ligands without major structural rearrangements of the binding site. Antigen specificity can be explained through conserved interactions of DB3 with the steroid D-ring, whereas some of the crossreactivity is realized through different binding orientations of the steroid skeleton that place the A-ring into alternative pockets on the antibody surface. The restricted gene usage of the VGAM3.8 family in the generation of anti-progesterone monoclonal antibodies may be explained by the specific interaction of VH hallmark residues with the steroid D-ring. This first detailed structure of steroid interactions with a protein could be applied to the understanding of general mechanisms of steroid recognition as well as in the design of specific binding sites for small hydrophobic ligands.
About this StructureAbout this Structure
1DBK is a Protein complex structure of sequences from [1]. Full crystallographic information is available from OCA.
ReferenceReference
Molecular basis of crossreactivity and the limits of antibody-antigen complementarity., Arevalo JH, Taussig MJ, Wilson IA, Nature. 1993 Oct 28;365(6449):859-63. PMID:8413674
Page seeded by OCA on Thu Mar 20 10:35:51 2008